Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine

Richard J. Knight, Ronald H. Kerman, Scott Zela, Jeannette Podbielski, Hemangshu Podder, Charles T. Van Buren, Stephen Katz, Barry D. Kahan

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background. This study aims to determine the impact of thymoglobulin- sirolimus-cyclosporine immunosuppression on the alloimune response of pancreas-kidney transplant recipients. Methods. Thirty-six pancreas transplant recipients received an induction protocol of thymoglobulin, sirolimus, reduced-dose cyclosporine, and corticosteroids. Ten recipients were also enrolled in a study to measure immune responsiveness. Flow PRA determined HLA antibody, donor-specific flow cytometry crossmatching (FCXM), T-cell subset, and suppressor cell assays were performed during the first posttransplant year. Results. One-year patient, kidney, and pancreas graft survivals were 97%, 94%, and 92%, respectively. There was one death and three graft losses. There were no acute rejection episodes. Recipients in the immune-monitoring study (n=10) displayed >80% depression of CD3, CD4, and CD8 (+) cell counts up to 3 months posttransplant. At transplantation 9/10 patients displayed <10% class I and no class II HLA antibody. By 3 months, 7/10 monitored recipients showed a transient elevation in class I HLA antibodies, including 2 patients who expressed >80% Flow PRA. One patient was pretransplant FCXM positive, whereas by 3 months posttransplant 2/10 patients demonstrated a positive FCXM. There were no clinical consequences of the presence of HLA antibody or the positive FCXMs. By 6 months, 7/9 patients demonstrated immunoregulatory suppressor cells. Conclusions. The absence of acute rejection events was likely due to inhibition of donor-specific immunity by the immunosuppressive regimen. Seventy percent of patients demonstrated an early, nondonor-directed HLA antibody response that had no adverse effect on graft function and 78% of the monitored patients displayed immunoregulatory cells probably contributing to the successful outcomes.

Original languageEnglish (US)
Pages (from-to)1101-1105
Number of pages5
Issue number8
StatePublished - Apr 2006


  • Immune monitoring
  • Immunosuppression
  • Pancreas transplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology


Dive into the research topics of 'Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine'. Together they form a unique fingerprint.

Cite this